|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
11,270,000 |
Market
Cap: |
274.31(M) |
Last
Volume: |
197,427 |
Avg
Vol: |
196,888 |
52
Week Range: |
$13.82 - $26.5 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
5,250 |
117,800 |
Total Buy Value |
$0 |
$0 |
$74,754 |
$2,088,813 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
5 |
21 |
Total Shares Sold |
0 |
0 |
0 |
27,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-10-18 |
4 |
OE |
$2.36 |
$1,761 |
D/D |
746 |
9,534 |
|
- |
|
Varian John |
Director and CEO |
|
2013-10-15 |
4 |
AS |
$4.60 |
$45,950 |
D/D |
(10,000) |
103,006 |
|
- |
|
Varian John |
Director and CEO |
|
2013-10-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
113,006 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-09-30 |
4 |
A |
$4.27 |
$1,958 |
D/D |
459 |
8,788 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-09-18 |
4 |
AS |
$4.53 |
$27,187 |
D/D |
(6,000) |
8,329 |
|
- |
|
Varian John |
Director and CEO |
|
2013-09-16 |
4 |
S |
$4.59 |
$45,862 |
D/D |
(10,000) |
103,006 |
|
- |
|
Varian John |
Director and CEO |
|
2013-09-16 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
113,006 |
|
- |
|
Baker Julian |
Director |
|
2013-08-19 |
4/A |
B |
$3.62 |
$9,983,203 |
I/I |
2,757,791 |
510,449 |
2.25 |
- |
|
Baker Julian |
Director |
|
2013-08-19 |
4 |
A |
$3.62 |
$9,983,203 |
I/I |
2,757,791 |
510,449 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-08-19 |
4 |
AS |
$3.74 |
$22,419 |
D/D |
(6,000) |
14,329 |
|
- |
|
Varian John |
Director and CEO |
|
2013-08-15 |
4 |
AS |
$3.92 |
$39,212 |
D/D |
(10,000) |
103,006 |
|
- |
|
Varian John |
Director and CEO |
|
2013-08-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
113,006 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2013-08-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
13,231 |
11,820 |
|
- |
|
Varian John |
Director and CEO |
|
2013-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
94,574 |
103,006 |
|
- |
|
Varian John |
Director and CEO |
|
2013-08-14 |
4 |
AS |
$3.86 |
$199,419 |
D/D |
(51,647) |
8,432 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-08-14 |
4 |
S |
$3.86 |
$40,621 |
D/D |
(10,520) |
20,329 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,748 |
30,849 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2013-08-14 |
4 |
S |
$3.86 |
$23,175 |
D/D |
(6,002) |
27,711 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2013-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,265 |
33,713 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2013-08-14 |
4 |
S |
$3.86 |
$28,951 |
D/D |
(7,498) |
25,051 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2013-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,064 |
32,549 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-07-18 |
4 |
AS |
$4.71 |
$28,233 |
D/D |
(6,000) |
4,101 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-07-18 |
4 |
OE |
$2.36 |
$16,371 |
D/D |
6,000 |
7,353 |
|
- |
|
Varian John |
Director and CEO |
|
2013-07-15 |
4 |
AS |
$4.81 |
$48,066 |
D/D |
(10,000) |
60,079 |
|
- |
|
Varian John |
Director and CEO |
|
2013-07-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
70,079 |
|
- |
|
597 Records found
|
|
Page 18 of 24 |
|
|